Methdilazine 

Methdilazine is an orally active antibiotic (histamine antagonist). Methdilazine can inhibit various mycobacterium with MIC values at 5-15 μg/mL in vitro and in vivo, which can be used for the research of infectious diseases^[1][2].

MIC: 5-15 μg/mL (mycobacterium)

Methdilazine (0-20 μg/mL approximately, 18 h) inhibits kinds of mycobacterium with MIC values ranging from 5 μg/mL to 15 μg/mL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Methdilazine (Intraperitoneal injection, 10 μg/gm body wt/day, 6 weeks) is antagonistic to mycobacteria in H₃₇Rv infected mice^[1].
Methdilazine (Oral administration, 10 mg/kg per day, 28 days) improves survival of Mycobacterium Tuberculosis (Mtb) H37Rv infected mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

296.43

C₁₈H₂₀N₂S

1982-37-2

CN1CC(CN2C3=C(C=CC=C3)SC4=CC=CC=C24)CC1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. A N Chakrabarty, et al. Antimycobacterial activity of methdilazine (Md), an antimicrobic phenothiazine. APMIS. 1993 Jun;101(6):449-54.  [Content Brief]

  [2]. Noton K Dutta, et al. Activity of the phenothiazine methdilazine alone or in combination with isoniazid or streptomycin against Mycobacterium tuberculosis in mice. J Med Microbiol. 2009 Dec;58(Pt 12):1667-1668.  [Content Brief]